GSE146612 amiodarone 2 v 3 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE146612_amiodarone_2_v_3_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE146612_amiodarone_2_v_3_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE146612_amiodarone_2_v_3_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE146612_amiodarone_2_v_3_human_up.

Results found

Linked to

 

Label

Description

 

Gene

synergin gamma

Gene

small nucleolar RNA host gene 29

Gene

tripartite motif containing 16 like (pseudogene)

Gene

colony stimulating factor 2 receptor subunit alpha

Gene

long intergenic non-protein coding RNA 3040

Gene

zinc finger protein 542, pseudogene

Gene

small nucleolar RNA host gene 33

Gene

long intergenic non-protein coding RNA 632

Gene

uncharacterized LOC124901321

Gene

IGFL2 antisense RNA 1


  • Gene

    small nucleolar RNA host gene 29


  • Gene

    tripartite motif containing 16 like (pseudogene)


  • Gene

    colony stimulating factor 2 receptor subunit alpha


  • Gene

    long intergenic non-protein coding RNA 3040


  • Gene

    zinc finger protein 542, pseudogene


  • Gene

    small nucleolar RNA host gene 33


  • Gene

    long intergenic non-protein coding RNA 632


  • Gene

    uncharacterized LOC124901321


  • Gene

    IGFL2 antisense RNA 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.